Trial Profile
A Phase 1, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to < 12 Years Old
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Tedizolid (Primary) ; Tedizolid (Primary)
- Indications Bacterial skin diseases; Gram-positive infections
- Focus Pharmacokinetics
- Sponsors Cubist Pharmaceuticals; Merck Sharp & Dohme
- 17 Mar 2021 Results assessing single-dose pharmacokinetics and safety study of tedizolid phosphate in Gram-positive infections in children particularly ABSSSIs, published in the Pediatric Infectious Disease Journal
- 09 Jan 2019 Status changed from recruiting to completed.
- 21 Sep 2017 Planned End Date changed from 27 Apr 2018 to 23 Mar 2019.